Viromed Medical AG, a medical technology company specializing in cold plasma technology, has published its half-year report for 2026, detailing advances in product development and market launch, and confirming its full-year guidance. The company, listed on the stock exchange since October 2022, is focused on expanding the use of cold plasma in medicine through its wholly owned subsidiary Viromed Medical GmbH. The report, issued via NEWMEDIAWIRE, highlights both operational milestones and financial results for the first six months of the year.
During the reporting period, Viromed continued preclinical development of PulmoPlas®, initiated OEM production of ViroCAP® for HELLMUT RUCK GmbH, and secured an exclusive sales partnership with NEBU-TEC for veterinary applications of PulmoPlas®. A significant regulatory achievement was the completion of the conformity assessment procedure for ViroCAP® med as a Class IIa medical device under the EU Medical Device Regulation (MDR). The official approval certificate was received in early July 2026, allowing sales of ViroCAP® med to commence. Additionally, the company was granted a research allowance of EUR 550,000 for research and development projects in cold plasma technology. CEO Uwe Perbandt commented, “We successfully continued developing our products in the first half of the year while also making important progress in preclinical research. The planned publication of the study results in a renowned scientific journal will further strengthen the scientific evidence supporting our cold plasma technology.”
Financially, Viromed generated consolidated revenue of EUR 2.5 million in the first half of 2026, up slightly from EUR 2.4 million in the same period of 2025. The net loss for the period was EUR 1.1 million, compared to EUR 0.8 million in the prior-year period. The increased loss was primarily due to expenses related to the comprehensive PulmoPlas® study and the approval and market launch of ViroCAP® med. Despite the loss, the company’s equity increased by 43.9% to EUR 9.5 million as of June 30, 2026, resulting in an equity ratio of 67.6%, up from 39.9% a year earlier. This improvement was largely due to a EUR 2.7 million loan from Perbamed Invest GmbH, which was reviewed and approved by the supervisory board and the company’s tax advisor.
Looking ahead, Viromed expects a significant increase in consolidated revenue and net income for the 2026 financial year, confirming the full-year guidance adjusted on May 8, 2026. The company’s strategic focus on product development and market launch, including the planned acquisition of relyon plasma GmbH, positions it to capitalize on the growing demand for cold plasma technology in medical and veterinary applications. The half-year financial statements are available on the Viromed Medical AG website. For more details, view the original release on www.newmediawire.com.
